Capital One National Association decreased its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 11.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 8,491 shares of the biopharmaceutical company’s stock after selling 1,143 shares during the period. Capital One National Association’s holdings in Alexion Pharmaceuticals were worth $1,015,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of ALXN. Valeo Financial Advisors LLC purchased a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at about $147,000. Dupont Capital Management Corp purchased a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at about $156,000. BT Investment Management Ltd purchased a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at about $165,000. Beacon Investment Advisory Services Inc. purchased a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at about $201,000. Finally, Invictus RG purchased a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at about $202,000. Institutional investors own 94.01% of the company’s stock.

Several analysts have commented on ALXN shares. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. Robert W. Baird upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 target price for the company in a report on Monday, December 18th. Royal Bank of Canada boosted their target price on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $170.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twenty-one have given a buy rating to the company’s stock. Alexion Pharmaceuticals has an average rating of “Buy” and a consensus target price of $152.77.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $113.97 on Wednesday. The company has a market capitalization of $25,588.69, a P/E ratio of 22.77, a P/E/G ratio of 1.08 and a beta of 1.16. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. Alexion Pharmaceuticals’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.26 EPS. analysts predict that Alexion Pharmaceuticals, Inc. will post 5.87 earnings per share for the current fiscal year.

In related news, EVP John B. Moriarty sold 3,363 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $115.70, for a total transaction of $389,099.10. Following the transaction, the executive vice president now directly owns 71,400 shares of the company’s stock, valued at approximately $8,260,980. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ludwig Hantson sold 13,245 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $1,540,525.95. Following the transaction, the chief executive officer now directly owns 131,425 shares in the company, valued at $15,286,041.75. The disclosure for this sale can be found here. Insiders have sold a total of 28,930 shares of company stock worth $3,378,199 over the last three months. 4.35% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Holdings Reduced by Capital One National Association” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2018/02/14/alexion-pharmaceuticals-inc-alxn-holdings-reduced-by-capital-one-national-association.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.